Spots Global Cancer Trial Database for Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Official Title: Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Study ID: NCT00226954
Conditions
Interventions
Study Description
Brief Summary: Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
Contact Details
Name: Dr. Sandy Srinivas
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
